Mark A Smith Selected Research

Inflammation (Inflammations)

4/2015	Antibodies against hemolysin and cytotoxic necrotizing factor type 1 (CNF1) reduce bladder inflammation in a mouse model of urinary tract infection with toxigenic uropathogenic Escherichia coli.
9/2012	Low-dose pterostilbene, but not resveratrol, is a potent neuromodulator in aging and Alzheimer's disease.
1/2010	Signaling effect of amyloid-beta(42) on the processing of AbetaPP.
1/2009	Reexamining Alzheimer's disease: evidence for a protective role for amyloid-beta protein precursor and amyloid-beta.
9/2008	Expression of CD74 is increased in neurofibrillary tangles in Alzheimer's disease.
4/2008	Current approaches in the treatment of Alzheimer's disease.
1/2007	Increased isoprostane and prostaglandin are prominent in neurons in Alzheimer disease.
1/2006	The cell cycle and hormonal fluxes in Alzheimer disease: a novel therapeutic target.
10/2005	The cell cycle in Alzheimer disease: a unique target for neuropharmacology.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mark A Smith Research Topics

Disease

206	Alzheimer Disease (Alzheimer's Disease) 01/2018 - 01/2002
46	Neurodegenerative Diseases (Neurodegenerative Disease) 10/2012 - 01/2002
29	Amyloid Plaque 05/2014 - 01/2002
24	Parkinson Disease (Parkinson's Disease) 10/2012 - 03/2002
19	Dementia (Dementias) 01/2018 - 01/2002
16	Substance-Related Disorders (Drug Abuse) 01/2022 - 11/2008
15	Cognitive Dysfunction 04/2014 - 05/2004
13	Neuroblastoma 01/2012 - 03/2003
10	Mitochondrial Diseases (Mitochondrial Disease) 06/2013 - 05/2002
9	Inflammation (Inflammations) 04/2015 - 10/2005
8	Schizophrenia (Dementia Praecox) 01/2022 - 08/2005
8	Disease Progression 01/2010 - 10/2004
8	Hypoxia (Hypoxemia) 01/2010 - 01/2003
7	Body Weight (Weight, Body) 10/2018 - 08/2003
7	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 10/2012 - 03/2002
7	Prion Diseases (Transmissible Spongiform Encephalopathies) 04/2011 - 04/2002
6	Obesity 05/2016 - 08/2003
5	Neoplasms (Cancer) 11/2020 - 07/2003
5	Infections 05/2013 - 04/2005
5	Tauopathies 07/2011 - 03/2003
4	Opioid-Related Disorders (Opiate Addiction) 04/2022 - 12/2017
4	Psychotic Disorders (Schizoaffective Disorder) 12/2011 - 08/2005
3	Major Depressive Disorder (Major Depressive Disorders) 01/2022 - 08/2013
3	Insulin Resistance 10/2018 - 03/2011
3	Cocaine-Related Disorders (Cocaine Addiction) 02/2012 - 04/2004
3	Diabetes Mellitus 01/2012 - 02/2005
3	Hyperglycemia 01/2012 - 03/2002
3	Iron Overload 08/2011 - 09/2005
3	Lewy Body Disease (Lewy Body Dementia) 01/2011 - 07/2009
3	Pathologic Processes 02/2010 - 09/2002

Drug/Important Bio-Agent (IBA)

55	Amyloid beta-PeptidesIBA 09/2010 - 01/2002
39	Proteins (Proteins, Gene)FDA Link 01/2014 - 01/2002
30	Amyloid (Amyloid Fibrils)IBA 05/2014 - 07/2002
25	MetalsIBA 02/2012 - 01/2002
23	IronIBA 08/2011 - 01/2002
21	Pharmaceutical PreparationsIBA 01/2021 - 09/2002
19	AntioxidantsIBA 07/2010 - 02/2002
17	Estrogens (Estrogen)FDA Link 04/2022 - 07/2003
13	GonadotropinsIBA 01/2018 - 11/2002
13	EnzymesIBA 01/2012 - 03/2003
13	Free RadicalsIBA 01/2010 - 04/2002
11	Luteinizing Hormone (Lutropin)FDA LinkGeneric 07/2014 - 11/2002
11	Nucleic AcidsIBA 03/2010 - 03/2002
10	Glucose (Dextrose)FDA LinkGeneric 10/2018 - 10/2005
9	LeptinIBA 10/2018 - 08/2007
9	RNA (Ribonucleic Acid)IBA 10/2012 - 03/2002
9	Reactive Oxygen Species (Oxygen Radicals)IBA 04/2012 - 01/2002
9	CopperIBA 08/2011 - 01/2002
8	Hormones (Hormone)IBA 04/2014 - 01/2004
8	Phosphotransferases (Kinase)IBA 03/2011 - 08/2006
7	Heme Oxygenase-1IBA 01/2010 - 03/2003
7	Amyloid beta-Protein Precursor (Amyloid Protein Precursor)IBA 01/2010 - 09/2002
7	Chelating AgentsIBA 01/2010 - 03/2003
6	SteroidsIBA 01/2018 - 01/2004
6	Peptides (Polypeptides)IBA 01/2013 - 04/2002
6	Oxidants (Oxidizing Agents)IBA 12/2009 - 02/2002
6	Heme (Haem)IBA 09/2009 - 03/2003
5	AntibodiesIBA 04/2015 - 03/2005
5	CholesterolIBA 06/2011 - 07/2002
5	tau Proteins (tau Protein)IBA 04/2008 - 03/2003
4	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 01/2020 - 09/2005
4	Gonadotropin-Releasing Hormone (GnRH)FDA Link 01/2018 - 04/2005
4	Cocaine (Cocaine HCl)IBA 06/2016 - 11/2008
4	Neuroprotective AgentsIBA 04/2014 - 11/2007
4	DNA (Deoxyribonucleic Acid)IBA 04/2012 - 03/2002
4	8-hydroxyguanosineIBA 03/2012 - 11/2002
4	Advanced Glycation End ProductsIBA 01/2012 - 05/2002
4	Insulin (Novolin)FDA Link 04/2011 - 02/2005
4	HomocysteineIBA 01/2010 - 06/2004
4	Amyloid Precursor Protein Secretases (beta-Secretase)IBA 01/2010 - 02/2008
4	LipidsIBA 01/2010 - 01/2005
4	Glycogen Synthase Kinase 3 betaIBA 05/2009 - 06/2004
4	Mitogen-Activated Protein KinasesIBA 03/2009 - 09/2002
4	Nitric Oxide (Nitrogen Monoxide)FDA Link 12/2006 - 03/2002
3	Antidepressive Agents (Antidepressants)IBA 01/2022 - 08/2013
3	metabotropic glutamate receptor 2IBA 01/2022 - 04/2004
3	Glutamate Receptors (Glutamate Receptor)IBA 01/2021 - 09/2002
3	Pro-Opiomelanocortin (Proopiomelanocortin)IBA 10/2018 - 08/2007
3	Leuprolide (Lupron)FDA LinkGeneric 01/2018 - 04/2006
3	Glutamic Acid (Glutamate)FDA Link 04/2016 - 09/2002
3	Cholinesterase Inhibitors (Anticholinesterases)IBA 01/2015 - 09/2005
3	Mitochondrial DNA (mtDNA)IBA 06/2013 - 03/2003
3	Neurotransmitter Agents (Neurotransmitter)IBA 09/2012 - 10/2005
3	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 05/2012 - 07/2003
3	NucleosidesIBA 03/2012 - 11/2002
3	ZincIBA 08/2011 - 11/2007
3	Prion ProteinsIBA 04/2011 - 04/2005
3	Leucine (L-Leucine)FDA Link 01/2011 - 11/2006
3	Biomarkers (Surrogate Marker)IBA 02/2010 - 11/2006
3	Amyloidogenic ProteinsIBA 02/2010 - 01/2004
3	Memantine (Namenda)FDA Link 02/2010 - 09/2005
3	IonsIBA 01/2010 - 07/2002
3	PresenilinsIBA 01/2010 - 10/2005
3	Presenilin-1IBA 01/2010 - 06/2002
3	Electron Transport Complex IV (Cytochrome c Oxidase)IBA 09/2009 - 03/2003

Therapy/Procedure

27	Therapeutics 01/2022 - 04/2002
5	Hormone Replacement Therapy (Therapy, Hormone Replacement) 01/2018 - 08/2004
5	Self Administration (Administration, Self) 06/2016 - 12/2011
3	Drug Therapy (Chemotherapy) 04/2022 - 04/2004
3	Estrogen Replacement Therapy 07/2014 - 03/2003